Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.

Psimei Pharmaceuticals is developing boron-based drugs for applications in Photon Activation Therapy (PAT). This involves the use of standard radiotherapy to activate boron-based compounds which selectively target solid tumours. This results in an amplification of the therapeutic effect of conventional radiotherapy. Pre-clinical data for Psimei's lead product, PP200PAT, has demonstrated 90% true cure rates at 6 months in tumour models compared with 30% for conventional radiotherapy alone. It also enabled much shorter treatment regimes - days as opposed to weeks. This drug is being prepared for clinical development.

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

Retroscreen Virology has developed a business system with two principal units. The first is a Clinical Services business built around Human Viral Challenge Model and the second is a Translational Research (Pre-Clinical) business, built around in-house expertise on testing antivirals and virucidals in-vitro.

Activate Immunotherapy (formerly NovaRx) is a clinical-stage immuno-oncology company based in San Diego, California. Activate utilizes a novel approach for activating the body's immune system to recognize and destroy cancer cells. The company's most advanced immunotherapy, Lucanix, has been tested in late stage clinical trials as a treatment for non-small cell lung cancer (NSCLC), the largest cancer indication in the world. Lucanix has promising Phase 2 and Phase 3 data. In Lucanix's Phase 2 trial, the company demonstrated a significant improvement in survival for NSCLC patients. NovaRx completed a 532 patient Phase 3 study in early 2013. While the Phase 3 study missed the statistical endpoint for approval, survival benefits were shown if non United States clinical sites were excluded, particularly with patients who started Lucanix treatment within 12 weeks of chemotherapy and/or patients with prior chemotherapy and radiation therapy. Activate's proprietary platform technology is applicable to other solid tumors.

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.